Basaglar (insulin glargine) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to: improve blood sugar levels in adults ...

The U.S. Food and Drug Administration on Wednesday approved Eli Lilly & Co's diabetes drug Basaglar, a cheaper version of Sanofi AG's top-selling drug Lantus. The drug, an injection known also as ...

Basaglar (insulin glargine) is a brand-name subcutaneous injection that’s prescribed for managing blood sugar levels in certain people. As with other drugs, Basaglar can cause side effects, such as ...

The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 ...

The U.S. Food and Drug Administration today approved Basaglar (insulin glargineinjection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 ...

The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...

The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on December 15 that BASAGLAR (insulin glargine injection 100 units/mL) is available by prescription in ...

INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is ...

The US Food and Drug Administration has granted tentative approval for the use of Eli Lilly/Boehringer Ingelheim’s basal insulin Basaglar, for long-lasting control of blood sugar levels in patients ...

If you have diabetes, your doctor might suggest Basaglar (insulin glargine) as a treatment option for you. It’s a prescription drug used to treat: type 1 diabetes in adults and children ages 6 years ...

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Eli Lilly & Co's diabetes drug Basaglar, a cheaper version ...